HEK293 Cells
B7H6, B7-H6, B7 Homolog 6
Greater than 95% as determined by SDS-PAGE.
NCR3LG1 Human Recombinant produced in HEK is a single, glycosylated polypeptide chain containing 477 amino acids (25-262 a.a) and having a molecular mass of 53.6 kDa. NCR3LG1 is fused to a 239 amino acid hIgG-His tag at C-terminus & purified by proprietary chromatographic techniques.
B7H6, B7-H6, B7 Homolog 6
HEK293 Cells
DLKVEMMAGG TQITPLNDNV TIFCNIFYSQ PLNITSMGIT WFWKSLTFDK EVKVFEFFGD HQEAFRPGAI VSPWRLKSGD ASLRLPGIQL EEAGEYRCEV VVTPLKAQGT VQLEVVASPA SRLLLDQVGM KENEDKYMCE SSGFYPEAIN ITWEKQTQKF PHPIEISEDV ITGPTIKNMD GTFNVTSCLK LNSSQEDPGT VYQCVVRHAS LHTPLRSNFT LTAARHSLSE TEKTDNFS
LE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG KHHHHHH
Natural Cytotoxicity Triggering Receptor 3 Ligand 1 (NCR3LG1), also known as B7-H6, is a protein encoded by the NCR3LG1 gene in humans. This ligand is a member of the B7 family and plays a crucial role in the immune system, particularly in the activation of natural killer (NK) cells. The recombinant form of this protein is often used in research to study its functions and interactions.
NCR3LG1 is primarily expressed on the surface of tumor cells and plays a pivotal role in the immune response against cancer. It interacts with the NKp30 receptor (NCR3) on NK cells, triggering their activation and cytotoxic response . This interaction leads to the destruction of tumor cells, making NCR3LG1 a critical component in the body’s natural defense against cancer .
The expression of NCR3LG1 is associated with various types of cancers, including hematologic malignancies and solid tumors. Its presence on tumor cells and its ability to activate NK cells make it a potential target for cancer immunotherapy . Researchers are exploring ways to harness this interaction to develop treatments that enhance the immune system’s ability to fight cancer.
Human recombinant NCR3LG1 is widely used in research to study its role in immune responses and its potential therapeutic applications. Studies have shown that manipulating the expression of NCR3LG1 or its interaction with NKp30 can influence the effectiveness of NK cell-mediated cytotoxicity . This has significant implications for developing new cancer treatments and understanding the mechanisms of immune evasion by tumors.